Thursday, January 26, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Antimicrobial Resistance

Carb-X Funds Techulon’s Rapidly Adaptable Nano Therapeutic in Fight Against Drug Resistant Bacteria

Techulon project is the 50th project funded by CARB-X since it was launched in 2016

by Global Biodefense Staff
November 11, 2019
Carb-X Funds Techulon’s Rapidly Adaptable Nano Therapeutic in Fight Against Drug Resistant Bacteria

CARB-X is awarding Techulon Inc., located in the Virginia Tech Corporate Research Center in Blacksburg, VA, USA, up to $785,000 in non-dilutive funding to develop a new class of antimicrobial that would kill drug-resistant bacteria by targeting specific genes critical to the bacteria’s survival.

The CARB-X award supports preclinical hit-to-lead development of Techulon’s drug candidates targeting Acinetobacter baumannii and Pseudomonas aeruginosa, two superbugs that have been identified by the World Health Organization (WHO) as ‘priority pathogens’ posing the greatest threat to global health and by the US Centers for Disease Control and Prevention (CDC) as ‘serious threats’ to human health.

The Techulon project is the 50th innovative antibacterial early development project funded by CARB-X, established in July 2016. To date, CARB-X has invested more than $150 million in non-dilutive funding to accelerate the development of antibiotics, vaccines, diagnostics and other life-saving products to address drug-resistant bacteria, with additional funds committed if projects achieve certain milestones. The CARB-X portfolio has 31 active projects in five countries.

Techulon is developing novel peptide-peptide nucleic acids (PPNAs) antimicrobial compounds using its RANT platform, which can reveal DNA sequences in genes that are essential for the survival of microbes. The drugs work by precisely targeting these genes in superbugs causing an infection, thereby killing them. The PPNAs are composed of cell-penetrating peptides (CPP) conjugated via linkers to a gene target-specific antisense peptide nucleic acid (PNA) sequence for improved delivery into the microbe cytoplasm, efficient binding to target mRNA, and inhibition of translation of the target gene.

“CARB-X is fighting the spread of drug-resistant bacteria by supporting the development of innovative therapeutics and other products that target the most serious bacterial threats. We are making progress,” said Kevin Outterson, Executive Director of CARB-X, which is based at the Boston University School of Law. “The Techulon project is in the early stages of development but if successful and approved for use in patients, it could represent major improvements in the way deadly infections are treated.” CARB-X is a consortium led by Boston University and funded by a global partnership.

Infections from drug-resistant A. baumannii and P. aeruginosa can be fatal and are particularly threatening for patients with weakened immune systems. There is an urgent need for new therapies to treat infections caused by microbes such as these that have developed resistance to current antibiotics, rendering these drugs ineffective.

Supporting Antibacterial Innovation

According to the WHO, an estimated 700,000 people die each year worldwide from bacterial infections. In the US, an estimated 23,000 people die each year from drug-resistant bacterial infections. In Europe, the number of deaths yearly is estimated at 33,000.

CARB-X partners have committed up to $500 million to invest in antibacterial R&D between 2016-2021. CARB-X’s goal is to support projects through the early phases of development through Phase 1, so that they will attract additional private or public support for further clinical development and approval for use in patients. These funds are in addition to investments made by the companies themselves. CARB-X provides between 80 and 90 percent of project costs, depending on the phase of development.

CARB-X is led by Boston University. Funding for the Techulon project is provided by the Biomedical Advanced Research and Development Authority (BARDA), the Wellcome Trust, Germany’s Federal Ministry of Education and Research (BMBF), and with in-kind support from National Institute of Allergy and Infectious Diseases (NIAID).

Tags: AntimicrobialsASPRAwardsHHSmRNA

Related Posts

DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies
Medical Countermeasures

NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy